cabozantinib plus pembrolizumab as first-line therapy for cisplatin-ineligible muc
Published 5 months ago • 50 plays • Length 2:19Download video MP4
Download video MP3
Similar videos
-
6:02
ev-103: ev pembrolizumab as a promising first-line option for urothelial carcinoma
-
3:57
pembrolizumab plus 5-fu and cisplatin for first-line treatment in...
-
1:23
how effective is pembrolizumab in cisplatin-ineligible bladder cancer? results from keynote-052
-
3:56
phase ii trial of pembrolizumab & cabozantinib in patients with recurrent metastatic hnscc
-
3:29
emerging roles of nivolumab and cabozantinib for renal cell carcinoma
-
3:54
papmet2: cabozantinib with or without atezolizumab in prcc
-
0:34
pembrolizumab plus enfortumab vedotin for bladder cancer
-
1:41
phase ii trial of pembrolizumab and cabozantinib in hnscc
-
6:13
single-agent atezolizumab supported for some cisplatin-ineligible muc patients | matthew galsky
-
1:09
futibatinib plus pembrolizumab for the treatment of advanced or metastatic urothelial carcinoma
-
3:25
enfortumab vedotin with pembrolizumab for bladder cancer
-
2:07
nivolumab plus gemcitabine-cisplatin shows benefit for locally advanced muc
-
3:34
abacus trial: preoperative atezolizumab in urothelial carcinoma
-
1:40
phase iii meteor trial: cabozantinib vs everolimus for advanced clear cell renal cell carcinoma
-
1:43
understanding variant histologies in urothelial carcinoma: io and cabozantinib's potential
-
0:55
dr. apolo on the combination of cabozantinib plus nivolumab in urothelial carcinoma
-
1:18
dr. plimack on combo of pembrolizumab/epacodostat in bladder cancer
-
2:35
cabozantinib most effective treatment for metastatic papillary kidney cancer
-
7:08
final analysis of the atlantis cabozantinib comparison